Partnering for Resilience: How Alliances Are Strengthening Pharma Supply Chains in 2026

ASHP reported 227 active drug shortages in its January 2001 to June 2026 statistics, with active shortages trending up for the second quarter in a row and almost half of new 2026 shortages involving sole-source products. FDA also notes that drug shortages can result from manufacturing and quality problems, delays, and discontinuations.

The response in 2026 is clear: pharma manufacturers need stronger partnerships across logistics, technology, CDMOs, regulators, and public-private networks. The original 2025 version of this SCW blog focused on new alliances as a resilience lever. This updated version reframes the topic for 2026 with current market signals and practical actions for pharma executives.

Why Pharma Supply Chain Resilience Is Still a Board-Level Priority in 2026

The pressure on pharma manufacturers has become more structural. A shortage today may start with one supplier, one quality event, one delayed batch, or one blocked logistics lane. The impact can spread quickly across wholesalers, hospitals, pharmacies, and patients.

This is why regulators are increasingly asking companies to move from reactive shortage management to proactive shortage prevention. EMA guidance for companies emphasizes early notification, shortage prevention and management plans, resilient multinational supply chains, pharmaceutical quality systems, and communication between supply chain stakeholders. EMA also notes that marketing authorization holders should be ready to implement shortage prevention plans before the expected legal deadline from mid-2027.

For a pharma manufacturer, the operating question is no longer simply, “Do we have enough inventory?” The stronger question is: can we see risk early, coordinate across partners, and recover quickly without losing control of quality, compliance, or patient supply?

That requires partnerships built into the operating model. Logistics partners provide controlled capacity and chain-of-custody visibility. CDMOs provide manufacturing flexibility and capacity options. Technology partners provide data visibility, AI-enabled decision support, and workflow automation. Public-private alliances help strengthen critical medicine supply where market economics alone may not solve the risk.

Pharma Manufacturer and Logistics Partnerships: Protecting Cold Chain, Speed, and Chain of Custody

Logistics partnerships are becoming more strategic because medicine portfolios are becoming more sensitive. Biologics, advanced therapies, injectables, vaccines, and specialty medicines often require strict temperature control, validated handling, reliable handoffs, and clear chain of custody.

In February 2026, DHL Group announced an expanded dedicated Airfreight Cold Chain Network for temperature-sensitive medicines, vaccines, pharmaceutical products, and cell and gene therapies. DHL described the network as part of a EUR 2 billion strategic investment in health logistics, with end-to-end visibility and more than 30 GDP-compliant aviation hubs and gateways.

UPS Healthcare announced a $48 million investment in 27 temperature-controlled freight cross-dock facilities across key global markets in 2026, positioning the investment around speed, visibility, chain of custody, and temperature-controlled handling for advanced therapies and other sensitive medicines.

What pharma manufacturers should expect from logistics partners

• GDP-compliant infrastructure and trained life sciences teams
• Temperature-controlled capacity across priority lanes
• Real-time visibility and exception alerts
• Chain-of-custody documentation
• Backup lane strategy for critical products
• Clear escalation procedures and service-level metrics
• Integration with planning, quality, and customer service teams

Pharma Manufacturer and Technology Partnerships: Digital Transformation for Visibility and Response

Digital transformation is now central to pharma supply chain resilience. Pharma manufacturers need connected data across production, quality, inventory, logistics, suppliers, and partners. Without that foundation, risk signals stay hidden until they become shortages, delays, or customer escalations.

A clear 2026 example is Merck’s partnership with Google Cloud to enhance Merck’s digital backbone as an AI-enabled enterprise. The partnership includes an agentic platform across R&D, manufacturing, commercial, and corporate functions, with Google Cloud engineers working alongside Merck teams using Gemini Enterprise.

For pharma manufacturers, technology should help teams answer key questions faster: which product, batch, lane, or supplier is at risk; where the delay is happening; what inventory can be reallocated; which partner needs escalation; and what action will protect service levels without creating compliance risk.

Pharma Manufacturer and CDMO Alliances: Securing Capacity and Flexibility

Manufacturing capacity has become one of the most important resilience levers for pharma manufacturers. A strong CDMO alliance can provide surge capacity, specialized technology, geographic diversification, and faster scale-up for complex products.

Samsung Biologics has continued to expand its manufacturing footprint and modality coverage. In December 2025, Reuters reported that Samsung Biologics agreed to buy its first U.S. drug production facility from GSK for $280 million. Samsung Biologics later stated that the Rockville, Maryland facility adds 60,000 liters of drug substance capacity. In 2026, Samsung Biologics announced an all-cash offer to acquire PolyPeptide, with an equity value of approximately CHF 1.46 billion.

What strong CDMO partnerships should include

• Long-term capacity planning and demand visibility
• Clear quality agreements and deviation escalation paths
• Tech transfer governance and site readiness milestones
• Joint risk reviews for critical materials and suppliers
• Digital integration for batch status, release status, and inventory visibility
• Backup production scenarios for critical products
• Executive governance with shared KPIs

Public-Private Alliances: Strengthening Critical Medicine Supply

Public-private alliances are playing a larger role in 2026 because some supply risks are too large for individual companies to solve alone. Critical medicines, essential APIs, domestic manufacturing, and shortage prevention often require coordination between regulators, manufacturers, procurement bodies, and policy makers.

In the EU, the Critical Medicines Act reached a provisional agreement between the Council and Parliament in May 2026. The agreement aims to improve security of supply and availability of critical medicines, diversify supply chains, support collaborative procurement, and strengthen manufacturing capacity for critical medicines and active ingredients within the EU.

In the U.S., FDA announced seven participants for the FDA PreCheck Pilot Program in June 2026. The program is designed to strengthen domestic pharmaceutical manufacturing, increase production capacity, and improve the resilience of the U.S. drug supply chain.

ASPR also announced an additional $8.3 million award in March 2026 to expand domestic manufacturing capacity for APIs used in essential hospital medicines, including propofol and metoprolol.

What Makes Pharma Supply Chain Partnerships Successful in 2026

Partnerships do not automatically create resilience. A pharma manufacturer can have many vendors and still lack coordinated response capability. The difference comes from governance, shared data, clear accountability, and measurable performance.

The best partnerships in 2026 behave like extended operating systems. Each partner knows what they own, what data they must share, what happens when an exception occurs, and how the group will recover from disruption.

Practical partnership checklist for pharma manufacturers

• Shared objective: clear definition of resilience, service level, quality, and patient impact
• Executive governance: steering committee, escalation paths, and decision rights
• Data visibility: agreed data fields, frequency, ownership, and system integration
• Joint risk register: top risks by product, site, supplier, lane, and market
• Scenario planning: shortage, quality hold, demand surge, lane disruption, and supplier failure
• Quality alignment: deviation handling, CAPA process, audit readiness, and regulatory responsibilities
• Commercial alignment: incentives that support service, flexibility, and long-term investment
• Digital operating model: dashboards, automation, alerts, and workflow ownership

What Pharma Manufacturers Should Do Next

Pharma manufacturers should treat 2026 as the year to formalize resilience partnerships before the next disruption exposes the gaps. Start with the most critical products, the most fragile suppliers, and the most constrained manufacturing or logistics lanes. Then build a partnership model that is visible, measurable, and repeatable.

Conclusion

In 2026, pharma supply chain resilience is shaped by a connected ecosystem: logistics partners that protect cold chain and chain of custody, technology partners that improve visibility and response, CDMOs that secure manufacturing capacity, and public-private alliances that strengthen critical medicine supply.

For a pharma manufacturer, the strategic advantage comes from designing these partnerships with governance, data, KPIs, and clear escalation paths. The organizations that move fastest will be the ones that treat resilience as a measurable operating model. They will know where the risks sit, which partners matter most, and how to respond before disruption affects patients.